[ad_1] PINGXIANG, China, Oct. 19, 2024 /PRNewswire/ — A report from Jiangxi International Communication Center(JXICC): Recently, a group of foreign journalists and bloggers from seven countries including the UK, Japan, South Korea, and Indonesia visited Pingxiang in […]
Trending Stories
Curio Digital Therapeutics Applauded by Frost & Sullivan for Enhancing Women’s Maternal Mental Healthcare with its MamaLift and MamaLift Plus Solutions USA – English India – English
[ad_1] MamaLift ensures personalized care tailored to each woman’s journey through motherhood, empowering them to manage stress, embrace joy, and reduce the risk of depression and anxiety during and after pregnancy. SAN ANTONIO, Oct. 19, […]
Accord Healthcare receives positive CHMP opinion for IMULDOSA®, a ustekinumab biosimilar to Stelara®
[ad_1] Accord announces that the CHMP has issued a positive opinion for Imuldosa® (development code: DMB-3115), a biosimilar to Stelara®, indicated for a range of immunology conditions. The approval of Imuldosa® further enhances Accord Healthcare’s biosimilar portfolio […]
Accord Healthcare erhält positive CHMP-Stellungnahme für IMULDOSA®, ein Ustekinumab-Biosimilar zu Stelara®
[ad_1] Accord gibt bekannt, dass der CHMP eine positive Stellungnahme für Imuldosa® (Entwicklungscode: DMB-3115), ein Biosimilar zu Stelara®, das bei einer Reihe von immunologischen Erkrankungen eingesetzt wird. Die Zulassung von Imuldosa® erweitert das Biosimilar-Portfolio von Accord Healthcare und […]
Accord Healthcare reçoit un avis positif du CHMP pour IMULDOSA®, un biosimilaire de Stelara Biosimilar à Stelara®.
[ad_1] Accord annonce que le CHMP a émis un avis positif pour Imuldosa® (code de développement : DMB-3115), un biosimilaire de Stelara®, indiqué pour une série de pathologies immunologiques. L’approbation d’Imuldosa® enrichit le portefeuille de biosimilaires d’Accord Healthcare et […]
